| Project/Area Number |
14207052
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
TATSUMI Eisuke National Cardiovascular Center Research Institute, Advanced Medical Engineering Center, Laboratory for Research Evaluation, Laboratory Chief, 研究評価室, 室長 (00216996)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAENAKA Yoshiyuki National Cardiovascular Center Research Institute, Advanced Medical Engineering Center, Deparment of Artificial Organs, Director, 人工臓器部, 部長 (00142183)
TAKEWA Yoshiaki National Cardiovascular Center Research Institute, Advanced Medical Engineering Center, Deparment of Artificial Organs, Senior Staff, 人工臓器部, 室長 (20332405)
NISHINAKA Tomohiro National Cardiovascular Center Research Institute, Advanced Medical Engineering Center, Deparment of Artificial Organs, Seniro Staff, 人工臓器部, 室長 (00256570)
HOMMA Akihiko National Cardiovascular Center Research Institute, Advanced Medical Engineering Center, Deparment of Artificial Organs, Staff, 人工臓器部, 室員 (20287428)
TSUKIYA Tomonori National Cardiovascular Center Research Institute, Advanced Medical Engineering Center, Deparment of Artificial Organs, Staff, 人工臓器部, 室員 (00311449)
|
|---|
| Project Period (FY) |
2002 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥32,760,000 (Direct Cost: ¥25,200,000、Indirect Cost: ¥7,560,000)
Fiscal Year 2005: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2004: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2003: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2002: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
|
|---|
| Keywords | percutaneous cardiopulmonary supprt (PCPS) / ventriculat assist device (VAD) / gene therapy / heart failure / heart transplantation / hepatic growth factro (HGF) / heparin-bonding surface treatment / antithorombogenic treatment |
|---|
| Research Abstract |
Concrete targets of this study are : 1) development of the next-generation PCPS system for emergency salvage of acute heart failure patients, 2) thorough improvement of the current pneumatic VAD system for long-term use with high QOL, 3) establishment of new treatment strategy by combination of VAD and regenerative medicine in order to overcome the lack of donor heart for transplantation. First, an extremely durable and antithorombogenic PCPS system was developed. The system installed in venoarterial bypass fashion in animal testing could be run for up to 150 days in adult model, and up to 67 days in pediatric model, without systemic anticoagulation. The oxygenator has been already commercialized in advance, and has been demonstrating excellent clinical PCPS outcomes. As for VAD system improvement, the blood pump was coated with a novel potent heparin-bonding material. After favorable experimental results, the heparin-coated VAD has been commercialized and brought into the clinical are
… More
na. The VAD driver was downsized through fundamental reform of driving mechanism to become carry-bag type with 12 kg in weight. This driver has been approved, and is about to be clinical use, although the prototype driver has been already applied to domestic and oversea transportations of VAD patients with great success and admiration. Further downsizing aiming at wearable driver continues, and until now the weight has been reduced to less than 3 kg. A skin button system for anti-drive line infection has been developed, which could be maintained for over 2 years without disinfectant treatment in animal experiment. The next-generation implantable blood pump for destination therapy has been also under development. About establishment of the new therapy strategy, significant functional recovery was confirmed by VAD support in combination with HGF gene therapy or bone marrow stem cell transplant by chronic animal experiment, successfully demonstrating the new possibility of higher weaning rate from VAD support, without receiving heart transplantation, by concomitant treatment with regenerative medicine. Less
|
